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Abstract
Background: Endometrial cancer incidence is continuing to rise in the wake of the current ageing and obesity epidemics.
Much of the risk for endometrial cancer development is influenced by the environment and lifestyle. Accumulating evidence
suggests that the epigenome serves as the interface between the genome and the environment and that hypermethylation
of stem cell polycomb group target genes is an epigenetic hallmark of cancer. The objective of this study was to determine
the functional role of epigenetic factors in endometrial cancer development.
MethodsandFindings:Epigenome-widemethylationanalysisof.27,000CpGsites inendometrial cancer tissue samples (n=64)and
control samples (n=23) revealed that HAND2 (a gene encoding a transcription factor expressed in the endometrial stroma) is one of
the most commonly hypermethylated and silenced genes in endometrial cancer. A novel integrative epigenome-transcriptome-
interactomeanalysis further revealed thatHAND2 is thehubof themosthighly rankeddifferentialmethylationhotspot in endometrial
cancer. These findingswerevalidatedusingcandidategenemethylationanalysis inmultiple clinical sample setsof tissuesamples from
a total of 272 additional women. Increased HAND2methylation was a feature of premalignant endometrial lesions and was seen to
parallel a decrease in RNA and protein levels. Furthermore, womenwith high endometrial HAND2methylation in their premalignant
lesions were less likely to respond to progesterone treatment.HAND2methylation analysis of endometrial secretions collected using
high vaginal swabs taken from women with postmenopausal bleeding specifically identified those patients with early stage
endometrial cancer with both high sensitivity and high specificity (receiver operating characteristics area under the curve=0.91 for
stage1Aand0.97 forhigher than stage1A). Finally,miceharbouringaHand2 knock-out specifically in their endometriumwere shown
to develop precancerous endometrial lesions with increasing age, and these lesions also demonstrated a lack of PTEN expression.
Conclusions: HAND2 methylation is a common and crucial molecular alteration in endometrial cancer that could potentially
be employed as a biomarker for early detection of endometrial cancer and as a predictor of treatment response. The true
clinical utility of HAND2 DNA methylation, however, requires further validation in prospective studies.
Please see later in the article for the Editors’ Summary.
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Introduction
Accumulating evidence suggests that the epigenome serves as
the interface between the genome and the environment [1,2] and
that hypermethylation of stem cell polycomb group target genes
(PCGTs—targets for chromatin-modifying complexes that tran-
siently suppress expression and temporarily repress cellular
differentiation required for development and stem cell renewal)
is an epigenetic hallmark of cancer [3,4]. PCGT methylation is
amongst the earliest molecular changes in human carcinogenesis
[5–7]. Several lines of evidence suggest that methylation of
PCGTs, as triggered by environmental factors and age [5,8],
reduces cellular differentiation, leading to an accumulation of
undifferentiated cells susceptible to cancer development [7,9,10].
Given that endometrial carcinoma risk is largely determined by
non-hereditary factors [11,12], including age, obesity, and
reproductive and environmental factors, it is an ideal disease
model to study to further our understanding of the epigenetic
mechanisms underlying cancer initiation and progression. While
oestrogen drives cell proliferation, progesterone inhibits prolifer-
ation of the endometrium and causes cell differentiation.
Conditions that are associated with a functional dominance of
oestrogen over progesterone (obesity, polycystic ovary syndrome,
nulliparity, long-term exposure to unopposed oestrogens) increase
the risk for endometrial cancer [13].
Although it is well established that the tumour-protective and anti-
proliferative effect of progesterone on the endometrial epithelium
[14] is mediated via progesterone receptor (PR) activity in the
endometrial stroma (and not directly via epithelial PR) [15], very little
is known about early molecular changes that contribute to the
development of this disease. Here we applied an epigenome-wide
approach in conjunction with a novel statistical algorithm to identify
genes that are epigenetically silenced early in endometrial carcino-
genesis. We validated our findings in multiple clinical sample sets and
provide a hypothesis regarding the genetic consequences of epigenetic
silencing using a conditional knock-out mouse model.
Methods
Analyses Synopsis
We analysed the DNA methylation (DNAme) of,27,000 CpGs
(Illumina Infinium HumanMethylation27K BeadChip) in normal
and cancerous endometrial tissue (Set 1) and applied a novel
integrative epigenome-transcriptome-interactome approach (by
also adding data from Set 2) to identify epigenetically deregulated
interactome hotspots of functional significance associated with the
phenotype of interest, i.e., endometrial cancer. The highest scoring
gene was HAND2, a gene encoding a transcription factor expressed
in the endometrial stroma. This result was further validated using
real-time PCR, MethyLight, and immunohistochemistry in
additional sample sets (Sets 3 and 5). The clinical potential of
HAND2 methylation detection as a marker of early events in the
development of endometrial cancer and as a predictor of
progesterone treatment response was studied using MethyLight
in Sets 4 and 6, respectively. The functional relevance of HAND2
silencing was addressed through the application of a conditional
knock-out mouse model.
Study Population
Set 1 (frozen tissue). Prospectively collected fresh-frozen
tumour tissue donated by consenting patients to a population-
based tissue bank at the Haukeland University Hospital, Norway,
were analysed. Age at diagnosis of endometrial cancer, Interna-
tional Federation of Gynecology and Obstetrics stage, histological
subtype and grade, treatment, and follow-up were registered. The
tumour tissue was consecutively examined by frozen sections to
verify high malignant epithelial component, with a minimum
cutoff for inclusion of 50% purity. Written consent was provided
by all patients. 64 endometrial cancer samples and 23 normal
endometrial samples from cancer-free women were assessed using
the Illumina Infinium HumanMethylation27K BeadChip array
(Table S1). All but one of the women were Caucasian. The study
was approved by the Regional Committee for Medical and Health
Research Ethics, Western Norway (NSD 15501). A total of 34
molecular markers were analysed as previously described [16–18].
Set 2 (mRNA dataset). This gene expression dataset
included 79 endometrioid stage I endometrial cancers and 12
samples of atrophic endometrium from postmenopausal women,
profiled using the Affymetrix Human Genome 133 Plus 2.0 Array
(GSE17025) as described in [19]. All samples were collected under
full ethical approval.
Set 3 (frozen tissue). 118 endometrial cancer samples and
27 control samples were available from the local biobank at the
Department of Gynaecology and Obstetrics, Innsbruck Medical
University (patients were treated between January 1989 and April
2000). All women providing tissue samples were Caucasian.
Sufficient quality and quantity of DNA was extracted from 101
endometrial cancer samples and 24 normal endometrium samples,
which were subsequently assessed using MethyLight (Table S2)
and quantitative real-time PCR to ascertain HAND2 DNAme and
mRNA expression status, respectively. Written informed consent is
not available from all patients; however, in accordance with the
Austrian law, the study was approved by the ethical committee of
the Innsbruck Medical University (reference number: UN4044-
290/4.9) and conducted in accordance with the Declaration of
Helsinki. All samples were anonymised to guarantee the protection
of privacy before performing the analysis.
Set 4 (vaginal swabs). Vaginal swabs were collected from
women who presented with postmenopausal bleeding to Univer-
sity College London Hospital or the five referring hospitals. Swabs
were taken prior to hysteroscopy/endometrial biopsy or hysterec-
tomy. A total of 131 consecutive women were recruited and
provided written informed consent. Of 131 swab specimens, 80
yielded DNA of sufficient quantity from the collection medium. Of
the 80 samples that passed DNA extraction, 48 samples were
finally assessed as full clinical information was available at the time
for these specimens. 17 women had no endometrial cancer on
histology (mean age 65 years). 18 had a stage 1A endometrioid
endometrial cancer (1, 11 and 6 had a grade 1, 2 and 3 cancer
respectively; mean age 65 years) whilst 13 had an endometrioid
endometrial cancer at more advanced stage (8, 3 and 2 had a stage
1B, 2 and 3 cancer, respectively). Of the 13 higher stage cancers, 1,
10 and 2 were grade 1, 2 and 3; mean age 66 years) (Table S3).
The study was approved by the Joint University College London/
University College London Hospital Committees on the Ethics of
Human Research (No 06/Q0502/89).
Set 5 (paraffin tissue). A total of 37 recently archived
formalin-fixed paraffin-embedded blocks were retrieved from the
pathology archives at the University College London Hospital
consisting of four histological subsets: (1) normal endometrium
(n=10) from women who had hysterectomy for benign diseases
(six for fibroids and four for prolapse, mean age 56.5 y), (2)
unaffected normal endometrium from women with complex
atypical hyperplasia (CAH) (n=7, mean age 58.7 y), (3) CAH
tissue (n=8, mean age 61.3 y), and (4) endometrioid endometrial
cancer (n=12, four samples for each of grade 1, 2, and 3 with
mean age 56.5 y, 68.8 y, and 68.5 y, respectively). The tissues
were analysed by independent gynaecological pathologists, and 26
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0.6-mm punch cores were taken from the formalin-fixed paraffin-
embedded samples using a tissue microarrayer prior to DNA
extraction. The study was ethically approved by the UCL Cancer
Institute and the UCL/UCLH Biobank for Studying Health and
Disease (reference number ECNC01.11). Written informed
consent was not obtained for these samples, but all samples were
anonymised so that patient information was protected and
confidentiality preserved in accordance with the UK Human
Tissue Act 2004.
Set 6 (endometrial biopsies). 74 women who underwent a
hysteroscopy and endometrial biopsy between 2009 and 2011 in
Prague and between 1999 and 2011 in Helsinki were retrospec-
tively and consecutively selected for this study. All women were
treated with progesterone because of a diagnosis of simple,
complex, or complex atypical hyperplasia, prior to a follow-up
hysteroscopy and second endometrial biopsy 3 months later. From
the 74 patients selected, 42 (mean age 56.2 y) provided sufficient
DNA from their initial endometrial biopsy (19, 12, and 11 had a
simple, complex, and complex atypical hyperplasia, respectively).
Sufficient paraffin tissue remained from 34 of the 42 samples for
additional immunohistochemical testing. Oral tibolone, dydroges-
terone, norethisterone, lynestrenol, and medroxyprogesterone
acetate were taken by one, three, four, six, and 24 women,
respectively, and four had a progesterone-containing intrauterine
device for at least 3 months. Patients were initially treated for
3 months, and the hysteroscopy/biopsy was repeated. If a patient
responded (i.e., normal endometrium on histology, n=29), the
treatment was stopped in Prague but continued in Helsinki for 3
additional months. No response after 3 months was observed in 13
patients. In the event of lack of response (hyperplasia on histology,
but no progression to atypical hyperplasia or cancer), patients were
treated for a further 3 months before a repeat biopsy was
performed. If there was still no response, as indicated by biopsy
at 6 months, a hysterectomy was recommended. Treatment
adherence was monitored according to standard clinical practice,
i.e., patient assessment. Written informed consent was provided by
all patients. The study was approved by the ethical committee of
the General University Hospital and Charles University Prague
First Faculty of Medicine (No. 1190/07 S-IV) and the Ethics
Committee of the Helsinki and Uusimaa Hospital District
(approval number 21/13/03/03/2012). Further details are
provided in Table S4.
DNA Methylation Assays
DNA extraction and bisulphite modification. Fresh tissue
(Sets 1 and 3), vaginal swabs (Set 4), and formalin-fixed paraffin-
embedded tissue (Sets 5 and 6) were extracted using the Qiagen
DNeasy Blood & Tissue Kit (69506) and the QIAamp DNA Mini
Kit (51304). All DNA samples were then bisulphite-modified using
the EZ DNA Methylation Kit D5008 (Zymo Research) according
to the manufacturer’s instructions.
Genome-wide DNA methylation analysis. Genome-wide
methylation analysis was performed as described using the
validated Illumina Infinium HumanMethylation27K BeadChip
[5]. HAND2 is represented by two CpG sites on the array, as
indicated in Figure 1E. The array methylation data are in good
agreement with the genes described in the past as hypermethylated
in endometrial cancer [20] (Figure S1). The Illumina Infinium
HumanMethylation27K DNAme data are available in the Gene
Expression Omnibus (accession number GSE40032).
HAND2 MethyLight. MethyLight was performed as previ-
ously described [21] using HAND2-specific primers and probes:
MethyLight HAND2 I: forward primer: TTAGTTTAGGAGA-
ATTATCGTCGTTATTTC, reverse primer: GAAAACCGC-
GACTCGAACTC, probe sequence: GAAAACCGCGACTC-
GAACTC; MethyLight HAND2 II: forward primer: GATT-
TTGCGTTTGGTTATTAGTTATATCG, reverse primer: CT-
CCGCCTCGCCATTCTA, probe sequence: TGGATTTGTT-
GGTTAAGGACGA. The percentage of methylated reference
(PMR) indicates the methylation level at the gene region assessed.
HAND2 Sequencing
Sanger sequencing was performed as outlined in Table S5.
HAND2 mRNA Expression and Immunohistochemistry
HAND2 mRNA expression analysis was performed as recently
described [22] using the following primers and probe: forward
primer: TTTTCTTGTCGTTGCTGCTCA, reverse primer:
AAGAAGACCGACGTGAAAGAGG, probe sequence: TTTC-
AAGATTTCGTTCAGCTCCTTCTTCCTCT. Santa Cruz
Biotechnology antibody (SC-9409) was used at a 1:250 dilution
on sections from paraffin-embedded tissue. The Allred Score (total
score = proportion score [0–5]+intensity score [0–3]) was used to
quantify the results.
Hand2 Conditional Knock-Out Mice Experiments
Mice (C57BL/6) were maintained in the designated animal care
facility at the University of Illinois College of Veterinary Medicine
according to the institutional guidelines for the care and use of
laboratory animals. The animals were housed in an Allentown 140
cage IVC system set at 60 air changes per hour at the cage level.
The mice were kept on Harlan 1/8 corncob and provided with
Harlan 8604 rodent diet. Harlan Iso-blox was provided for
environmental enrichment. Rooms were kept on a 12 h/12 h
light/dark cycle, and the temperature was set at 72uF with
35%64% relative humidity. Drinking water was filtered and
chlorinated. All animal care, euthanasia, and tissue collection
protocols strictly adhered to US National Institutes of Health and
institutional guidelines for the use of laboratory animals. All
animal protocols were reviewed and approved by the Institutional
Animal Use and Care Committee of the University of Illinois.
Hand2 conditional knock-out mice (Hand2d/d) were generated by
crossing PR-Cre knock-in mice with Hand2 floxed mice (Hand2f/f)
mice as described previously [23]. Hand2 conditional knock-out
females (Hand2d/d) and the littermate controls (Hand2f/f) (n=24)
were randomly divided into three groups and housed at 2–4 mice
per cage. Uterine histology was assessed by hematoxylin and eosin
staining or immunohistochemistry at 8–10 (n=5 for each
genotype), 24–32 (n=3 for each genotype), and 40–48 wk of age
(n=4 for each genotype). Genotyping was performed based on
standard protocol using purified mouse tail DNA. Hand2f/f PRcre/+
males and Hand2f/f females were used as breeding pairs to generate
Hand2 conditional knock-out females (Hand2d/d) and the corre-
sponding littermate controls (Hand2f/f). Female mice between 8–
10, 24–32, and 40–48 wk of age were euthanized by carbon
dioxide inhalation at the designated space in the laboratory.
Uterine tissues were excised, trimmed, and collected. Uterine
segments were fixed in 10% formalin fixative overnight, then in
75% ethanol for paraffin embedding. Paraffin-embedded endo-
metrial tissue obtained from Hand2d/d and Hand2f/f animals were
sectioned at 4 mm, mounted on slides, and subjected to
immunohistochemistry as described previously [23]. Briefly,
uterine sections were incubated at 4uC overnight with polyclonal
antibodies against cytokeratin 8 and Ki67. Further incubation was
carried out with the biotinylated secondary antibodies at room
temperature, followed by incubation with horseradish-peroxidase-
conjugated streptavidin (Zymed Laboratories). The sections were
stained in AEC Solution (Zymed Laboratories) until optimal signal
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was obtained. For immunofluorescence the uterine sections were
deparaffinised using xylene, and then rehydrated. Antigen
retrieval was carried out by boiling the sections in 0.1 M citrate
buffer (pH 6.0). Sections were then incubated with normal serum
for an hour at room temperature, followed by incubation with the
primary antibody overnight at 4uC. Sections were washed in PBS
and incubated with secondary antibody linked to fluorochrome for
30 min at room temperature. Sections were washed in PBS and
mounted with a coverslip. Negative controls included incubation
with normal IgG and omission of the primary antibody (Figure
S2). The following primary antibodies were used: PTEN
(Millipore, catalog #04-035, 1:200), p-FRS2 (R&D Systems,
catalog #AF 5126, 1:200), and p53 (Santa Cruz Biotechnology,
catalog #SC-6243, 1:100); secondary antibody for immunofluo-
rescence was from Jackson ImmunoResearch.
Statistical Analyses
A logistic regression approach was used to model the association
between endometrial cancer status (cancer versus normal) and the
CpG b-value methylation profile. p-Values were estimated using
likelihood ratio tests. To correct for multiple testing, we estimated
the false discovery rate using the q-value estimation procedure
[24].
Gene Set Enrichment Analysis (GSEA) is a statistical procedure
used to test the hypothesis that a ranked list of genes is enriched for
specific biological terms or molecular pathways [25]. As a database
of biological terms and pathways (over 6,000 biological terms) we
used a recent version of MSigDB Molecular Signatures Database
(version 3.0). We also used a term annotated as PolyComb Group
Targets from Lee et al [26]. GSEA was performed by computing
enrichment odds ratios, with statistical significance estimated using
Figure 1. Discovery of HAND2 methylation as a core feature in endometrial cancer. (A) Volcano plot of epigenome-wide differential
DNAme analysis for all 27,578 probes. The x-axis indicates the median b-value difference between the normal and cancerous endometrial samples
(median[cancer] – median[normal]), while the y-axis indicates the 2loge scale of q-values obtained from a supervised logistic regression analysis
testing the association of methylation with normal/cancer status (Set 1). Stem cell PCGT CpGs are highlighted in green, the two HAND2 CpGs in red.
353 PCGT CpGs are hypermethylated, and 19 PCGT CpGs are hypomethylated, with enrichment odds ratio (OR) and p-value (P) obtained from a one-
sided Fisher’s exact test. The horizontal dotted lines mark the significance cutoffs. (B) Integrative DNA methylome (DNAm)–interactome analysis to
identify differential methylation hotspots in the network. Briefly, edge weights in the interactome network reflect the combined differential
methylation statistics (absolute values) of the genes making up the edge (the CpG closest to the transcription start site [TSS] of the gene was chosen).
A spin-glass module detection algorithm was subsequently used to identify subnetworks where the average edge weight (‘‘modularity’’) is higher
than random, as assessed by randomly rewiring the network preserving node degrees. Statistical significance of the subnetworks was further
assessed by comparing their modularities to those obtained by permuting differential methylation statistics over the network. Subnetworks with
p,0.05 were called EpiMods. (C) Bar plot of modularity values of the top 19 EpiMods with seed genes as indicated. Asterisks mark those hotspots that
remain significant in an integrated DNAme and gene expression interactome analysis, i.e., FEM analysis. (D) The HAND2 EpiMod. (E) The location of
Illumina Infinium HumanMethylation27K array HAND2 probes and MethyLight reactions (incorporating [inc.] the Illumina HAND2 CpGs) and the
sequenced region (grey bar) of HAND2. hyperM, hypermethylation; hypoM, hypomethylation.
doi:10.1371/journal.pmed.1001551.g001
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a one-tailed Fisher’s exact test. p-Values from this test were
corrected for multiple testing using the Benjamini-Hochberg
procedure [27]. GSEA was performed separately for top-ranked
hypermethylated and hypomethylated CpGs, and at the gene level
in order to avoid overcounting multiple CpGs mapping to the
same gene.
The Functional Epigenetic Modules (FEM) algorithm is a novel
direct extension of the EpiMod algorithm developed by us
previously [28]. Full details can be found in Text S1. Briefly, it
is an integrative epigenome-transcriptome-interactome approach
that aims to identify epigenetically deregulated interactome
hotspots of functional significance associated with a phenotype of
interest, here, endometrial cancer. There are two main steps to the
algorithm (see Figure S3). First, DNAme levels of gene promoter
regions are integrated with a human interactome to identify
differential methylation hotspots associated with endometrial
cancer. A differential methylation hotspot represents a closely
connected subnetwork of gene promoters whose genes interact at
the protein level and for which a significant number of gene
promoters are differentially methylated in endometrial cancer.
These hotspots (or epigenetic modules [EpiMods]) are identified
using a powerful module detection algorithm as described and
validated by us in detail in [28]. Second, to assess functional
significance, the inference of modules is repeated by further
integration with mRNA expression data (full details provided in
Text S1). Specifically, the algorithm detects modules that are
deregulated at both the DNAme and mRNA expression levels,
and in a manner that is consistent with the expected anti-
correlation between promoter DNAme and mRNA expression.
Modules that are robust and remain significant under the
integrated mRNA expression and DNAme analysis are deemed
candidate functional EpiMods. The EpiMod and FEM algorithms
are freely available as executable R-scripts from http://code.
google.com/p/epimods/downloads/list.
The performance of the diagnostic test to distinguish endome-
trial cancers from non-cancers is assessed by computing the
sensitivity and specificity across a range of thresholds, thus
generating receiver operating characteristic (ROC) curves, repre-
senting plots of sensitivity (y-axis) against 1 – specificity (x-axis).
The area under the ROC curve (AUC) represents a threshold-
independent measure of how well the test can discriminate the two
phenotypes. The asymptotic confidence interval of the AUC and
non-parametric hypothesis-testing p-values were calculated using
SPSS Statistics version 21 (IBM).
The numerical values prepared from at least three independent
samples of mice were analysed by t-test when comparisons were
made between control and experimental groups (GraphPad Prism
4.0, GraphPad Software). Data are expressed as mean 6 standard
error of the mean.
Results
HAND2 Is the Top-Ranked Differential Methylation
Interactome Hotspot in Endometrial Cancer
We performed DNAme profiling of 27,578 CpGs in 23 normal
and 64 cancerous endometrial samples (Set 1; Table S1). Principal
component analysis demonstrated that the top component,
accounting for over 90% of the variation in the data, was strongly
associated with DNAme differences between normal and cancer-
ous endometrium (Wilcoxon rank sum test p,10210; Figure S4).
Using logistic regressions and adopting a q-value (false discovery
rate) threshold of ,0.1, we identified 2,347 CpGs that were
hypermethylated (Table S6), and 1,024 CpGs that were
hypomethylated in cases versus controls (Figure 1A). GSEA
demonstrated very strong enrichment of EED, SUZ12,
H3K27me3, and PRC2 targets, demonstrating that PCGTs are
preferentially methylated in endometrial cancer (Figure 1A; odds
ratio 5.69 [95% CI 4.91–6.60], p,10250; see also Tables S7 and
S8).
In order to identify pathways and gene modules that are
aberrantly regulated at the epigenetic level, we developed a novel
integrative epigenome-transcriptome-interactome approach that
infers differential methylation interactome hotspots of functional
significance (Figure S3). The resulting algorithm, FEM, is an
extension of the EpiMod algorithm developed by us previously
[28]. The EpiMod algorithm was extensively tested and validated
on independent data and shown to outperform other competing
module detection algorithms [28]. Briefly, the algorithm integrates
the DNAme data with a human protein interactome to identify
gene promoters, not only according to their level of differential
methylation in cancer, but also according to whether they define
differential methylation interactome hotspots (EpiMods)
(Figure 1B). These EpiMods constitute densely connected subnet-
works where a significant number of gene promoters exhibit
differential methylation. FEM extends the EpiMod algorithm by
incorporating gene expression data in an integrative analysis that
aims to identify EpiMods that are also functionally deregulated
(Figure S3).
We identified a total of 19 significant EpiMods, with HAND2
emerging as the hub of the top-ranked EpiMod (Figure 1C and
1D; Tables S9 and S10). Importantly, the two CpG probes on the
Illumina Infinium HumanMethylation27K BeadChip array
mapping to HAND2 ranked highly among all hypermethylated
CpGs (Figure 1A and 1E; Table S6). Furthermore, the HAND2
EpiMod was a significantly functionally deregulated hotspot
under the FEM analysis that incorporated independent gene
expression data (12 normal and 79 cancerous endometrial
samples—Set 2 [19]) (Figure 1C), with HAND2 demonstrating
concordant underexpression in endometrial cancer (Figure S5).
All EpiMods demonstrated strong enrichment for biological
terms (Table S11), with the HAND2 EpiMod itself highly
enriched for other transcription factors (e.g., GATA4, HEY2,
HOXD13, PHOX2A, HAND1), all of which were also hypermethy-
lated in endometrial cancer (Figure S6). All these results indicate
that HAND2 and the interaction neighbourhood of HAND2,
including GATA4, HEYL, and PHOX2A, represent a core
component that is epigenetically deregulated in endometrial
cancer. Interestingly, the hub of the second top-ranked EpiMod
was DCC, a putative tumour suppressor [29]. However, although
DNAme of DCC strongly correlated with that of HAND2 (Figure
S7), the DCC EpiMod did not represent a functionally deregu-
lated hotspot (Figure 1C). Consequently, our novel bioinformatic
analysis led us to further investigate the role of HAND2 in
endometrial cancer.
The relevance of HAND2 in endometrial cancer is supported by
several lines of published evidence. First, HAND2 is a basic helix-
loop-helix transcription factor and developmental regulator [30],
as well as a stem cell PCGT [26]. Second, it is expressed in the
normal endometrial stroma, with its key physiological function
being to suppress the production of fibroblast growth factors that
mediate the paracrine mitogenic effects of oestrogen on the
endometrial epithelium [23]. Finally, HAND2 is regulated by
progesterone [31,32] and is integral for the progesterone-mediated
suppression of oestrogen-induced pathways, with the absence of
HAND2 resulting in impaired implantation [23]. Given this
evidence, we postulated that epigenetic deregulation of HAND2
could represent a key step in endometrial carcinogenesis.
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HAND2 Methylation Is Associated with HAND2
Suppression
We decided to first validate our array-based data using
MethyLight, an alternative real-time-PCR-based assay to study
DNAme, in a reaction spanning 5–7 linked CpGs, designed to
include those CpGs representing HAND2 on the Illumina array
(Figure 1E). MethyLight was carried out in an additional
independent set (Set 3) of endometrial cancers (n=101) and 24
normal endometrial samples from cancer-free women (Table S2).
There was a noticeable correlation between the methylation status
of the two individual Illumina CpG assays as well as between the
two MethyLight reactions incorporating these assays (Figure S8).
The MethyLight data confirmed a significantly higher methylation
in endometrial cancer samples (Figure 2A).
To validate the impact of HAND2 methylation on mRNA
expression, we measured HAND2 mRNA expression in the
samples of Set 3. Almost all endometrial cancer samples were
strongly methylated and demonstrated a significant suppression of
HAND2 mRNA (p,0.001; Figure 2A). In contrast, all of the
normal endometrial samples demonstrated low DNAme levels and
correspondingly high mRNA expression levels (Figure 2A).
HAND2 Methylation Is the Most Common Molecular
Alteration in Endometrial Cancer
To assess the relative importance of HAND2 methylation in
human endometrial carcinogenesis, we tested for any associations
between HAND2 methylation and well-known molecular charac-
teristics of the tumours (Table S12). Aside from subtle associations
of HAND2 methylation with oestrogen and progesterone receptor
immunohistochemistry, p53 expression, and FGFR2A mutation
status, none of the 30 (Table S12; Figure 2B) remaining molecular
features we tested exhibited an association with HAND2 methyl-
ation. Furthermore, the quantitative difference in HAND2
methylation between normal and cancer tissue was significantly
greater than the differences observed between molecular cancer
subgroups (compare Figure 2A and 2B). Most importantly,
HAND2 methylation was observed in over 90% of endometrial
cancers (Figure S6), and thus represented, by far, the most
frequent molecular alteration. Sequencing of the 59 region of
HAND2 (see Figure 1E) further excluded local changes in DNA
sequence as a trigger of HAND2 DNAme (Table S5; Figure S9).
Finally, HAND2 DNAme was not associated with any clinico-
pathological features including grade, stage, and histology, or with
clinical outcome in Set 1 (Table S1). In Set 3 there was no
association with histology or outcome, but we did observe a trend
towards higher methylation in lower stage and lower grade cancers
(Table S2). Thus, we can conclude that HAND2 methylation is a
common feature of endometrial cancer, largely independent of
sequence variants, clinicopathological characteristics, and specific
molecular endometrial cancer subgroups.
HAND2 Methylation in Vaginal Fluid Allows for Early
Detection of Endometrial Cancer
As DNAme analysis is amenable to assessment in bodily fluids,
we investigated the potential diagnostic utility of HAND2
methylation to identify women with suspected endometrial cancer
because of presentation with postmenopausal bleeding. We
prospectively collected high vaginal swabs to sample DNA that
had drained from the endometrial cavity from (1) 18 women later
confirmed to have a stage 1A endometrial cancer, (2) 13 women
with an endometrial cancer at more advanced stage, and (3) 17
women who were cancer-free (Set 4). We performed MethyLight
of HAND2 DNAme and calculated the AUC to assess the
sensitivity and specificity of the test: the AUC values were 0.91
and 0.97 for stage 1A (Figure 2C) and higher than stage 1A (Figure
S10) endometrial cancers, respectively.
HAND2 Methylation Is an Early Event in Endometrial
Carcinogenesis
As HAND2 DNAme was a confirmed feature of endometrial
cancer, we next sought to determine at which point during
endometrial carcinogenesis HAND2 becomes aberrantly methyl-
ated. We measured HAND2 DNAme in an endometrial cancer
progression series (Set 5) including (1) histologically normal
endometrium from women without any endometrial pathology,
(2) adjacent histologically normal endometrium from women who
had areas of CAH elsewhere in their endometrium, (3) CAH
lesions, and (4) invasive endometrioid endometrial cancer tissue
samples. HAND2 DNAme in the normal endometrium from
women without endometrial pathology was virtually undetectable
but was significantly increased in normal endometrium samples
from women with CAH, and further still in both CAH lesions and
cancerous endometrial tissue (Figure 3A). Importantly, HAND2
DNAme analysis was able to discriminate normal endometrial
tissue from confirmed CAH cases versus normal endometrial tissue
from healthy controls: AUC of 0.80 (p=0.04).
HAND2 Methylation in Hyperplastic Endometrium
Predicts Response to Progesterone
Although we have clearly shown that HAND2 methylation
precedes the development of endometrial cancer, it is still unclear
whether epigenetic silencing of HAND2 can be functionally linked
to endometrial cancer development. The sole way to demonstrate
this in humans is to test whether activation of HAND2 expression
(via its upstream regulator progesterone) is associated with a
change of endometrial histology. If HAND2 is silenced by DNAme,
one would expect no effect of progesterone. As progesterone
response is reliant upon HAND2 expression in the endometrium
[23], we examined whether HAND2 methylation in non-cancerous
hyperplasia of the endometrium is functionally associated with
response to progesterone treatment, typically administered as an
alternative to hysterectomy. We assessed 42 pre-treatment
endometrial biopsy samples (Set 6) and observed a significant
increase of HAND2 methylation, and concurrent decrease of
HAND2 protein expression, with premalignant disease progres-
sion (Figure 3B). As expected, HAND2 protein expression was
confined to the stroma and not the glandular epithelium in both
normal and simple hyperplastic tissue, which demonstrated very
low HAND2 DNAme despite an increase in the glandular/stromal
ratio. Furthermore, we observed that HAND2 methylation levels
were significantly higher in women who did not respond to a 3-mo
progesterone treatment period compared to women whose
endometrial lesions regressed after treatment (Figure 3C). The
AUC of HAND2 methylation to predict lack of response to
progesterone was 0.77 (p=0.005).
Conditional Knock-Out of Hand2 in Uterine Tissue Leads
to Complex Atypical Hyperplasia as a Function of Age
In humans, age and a history of long-term progesterone/
oestrogen imbalance (for which HAND2 methylation may poten-
tially be the resulting final molecular surrogate) are the major risk
factors for endometrial cancer. Hence, to further investigate the
functional role of HAND2 silencing in the earliest stages of
endometrial cancer development, we studied changes in endome-
trial histology as a function of age in mice with a conditional
knock-out of Hand2 in uterine tissue. As in a previous study [23],
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mice harbouring the floxed Hand2 gene (Hand2f/f) were crossed
with PR-Cre mice (in which Cre recombinase was inserted into the
PR gene) in order to generate Hand2d/d mice in which the Hand2
gene is deleted selectively in cells expressing PR (these mice
express a fully functional PR [23]). Both Hand2d/d and Hand2f/f
mice were healthy before tissue collection. No differences in
appearance or body weight were observed between these two
groups. Representative uterine sections obtained from Hand2f/f
and Hand2d/d mice (n=24) that were studied at 8–10, 24–32, and
40–48 wk of age are shown in Figure 4A–4F. We observed a
significant increase in the gland/stroma ratio (Figure 4G) and an
irregularity in the shape and size of the glands in Hand2d/d uteri
Figure 2. Association of HAND2methylation with molecular and clinical features in invasive endometrial cancer. (A) Scatter plot of the
MethyLight PMR profile and the gene expression profile of sample Set 3 showing 24 normal endometrium samples (in green) and 101 endometrial cancer
samples (in red). The correlation between the two profiles was tested by the Spearman’s rank correlation test with the correlation coefficient r and
corresponding p-value (P). (B) Analysis of 34 molecular factors and association with HAND2 methylation (Set1; Table S12). The nine molecular cancer
subgroups with significant heterogeneity between samples are displayed, and the p-values for the Wilcoxon rank sum test (WT) and t-test (TT) are provided
separately. Boxes aremedian (interquartile range), andwhiskers indicate range. (C) ROC curvesmeasuring the sensitivity and specificity ofHAND2methylation
in vaginal swabs to discriminate women with stage 1A endometrial cancer (n=18) from women with non-cancerous causes (n=17) for postmenopausal
bleeding (Set 4). PMR values as continuous variables were used for the analysis. AUC and p-values (P) as specified. IHC, immunohistochemistry; mut, mutation.
doi:10.1371/journal.pmed.1001551.g002
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compared to Hand2f/f uteri with increasing age (Figure 4A–4F). In
addition, the endometrium of Hand2d/d mice demonstrated clear
histological features of CAH (Figure 5A and 5B), including
increased mitotic activity (Figure S11). This indicates that
disruption of Hand2-mediated signalling solely in cells expressing
the PR leads to morphological changes in the endometrium (i.e.,
CAH) associated with a very high likelihood of invasive
endometrial cancer development [33].
Conditional Knock-Out of Hand2 in Uterine Tissue Leads
to Molecular Changes Commonly Observed in Human
Endometrial Cancer
In the uterine stroma Hand2 suppresses the production of
several fibroblast growth factors (FGFs) that act as paracrine
mediators of the mitogenic effects of oestrogen on the epithelium
[23]. FGF receptor substrate 2 (FRS2) participates in the
transmission of extracellular signals from the FGF receptor, and
activation of the FGF receptor and phosphorylation of FRS2 [34]
are a crucial event for the development of some cancers. Hand2
conditional knock-out mice demonstrate substantially increased
epithelial phospho-FRS2, indicating an increase of FGF receptor
signalling in Hand2-null mice during uterine hyperplasia
(Figure 5C–5F).
PTEN mutation and suppression has been shown to be one of
the earliest and most frequently observed features in human
endometrial carcinogenesis, and in mice, loss of Pten is sufficient to
cause endometrial carcinogenesis [35]. Unlike control mice, Hand2
conditional knock-out mice lack Pten expression in the endome-
trial epithelium (Figure 5G–5J), suggesting that HAND2 silencing is
a crucial step in endometrial carcinogenesis. In contrast, altered
Figure 3. HAND2 methylation in human endometrial carcinogenesis. (A) Boxplot comparing the differences in the HAND2 MethyLight PMR
profiles in endometrial samples from women without any endometrial pathology (N [Normal], n= 10), in normal endometrium from women with CAH
(N [CAH], n= 7), in CAH samples (CAH, n= 8), and in endometrioid endometrial cancer samples (Endo CA, n= 12). (B) Boxplots (top panel) comparing
DNAme (MethyLight) and HAND2 protein expression (immunohistochemistry quantified by means of the Allred Score) in three different endometrial
conditions with increasing potential for malignant transformation (simple hyperplasia [SH], n=17; complex hyperplasia [CH], n= 10; CAH, n= 7). The
lower panel gives an example of the corresponding HAND2 nuclear protein expression in stromal cells in simple hyperplasia compared to loss of
stromal expression in CAH. (C) Boxplot comparing the differences in the HAND2 MethyLight PMR profiles in endometrial cancer from patients treated
with progesterone according to whether they had clinically responded (n=29) or were non-responsive (n=13) to treatment. All p-values were
obtained from the two-sided Wilcoxon rank sum test. Boxes are median (interquartile range), and whiskers indicate range.
doi:10.1371/journal.pmed.1001551.g003
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Figure 4. Endometrial hyperplasia in Hand2 conditional knock-out mice as a function of age. (A–F) Sections of uteri obtained from
Hand2f/f (control) and Hand2d/d (null) mice were subjected to immunohistochemical staining with an antibody to cytokeratin 8, which marks the
epithelial cells. Uterine sections were collected from mice of both genotypes at different ages. Representative uterine sections obtained from mice
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p53 expression is not an early event in human endometrial
carcinogenesis [36], and our findings in mice are consistent with
this observation (Figure S12).
Discussion
Whereas there is little doubt that genetic alterations are required
for cancer development, the causal role of the epigenome in this
process is still under debate. Here we used a multifaceted
approach to assess the role of DNAme in endometrial carcino-
genesis. We began with a novel bioinformatics strategy—the
EpiMod algorithm—to identify the top candidates most likely
involved in endometrial carcinogenesis. We then sequenced the
top-ranked gene—HAND2—and validated DNAme and RNA
expression of this gene in an additional set of endometrial cancer
and control tissues and, furthermore, compared HAND2 methyl-
ation to other common molecular alterations in endometrial
cancer. We studied HAND2 methylation and protein expression at
various stages of endometrial premalignant development and
confirmed that methylation of this gene is an early event. We
found that HAND2 methylation is able to predict response to
progesterone and provides a sensitive test to correctly identify
endometrial cancer patients amongst those women who present
with postmenopausal bleeding through the DNAme analysis of
endometrial secretions on high vaginal swabs. Finally, we studied
the effect of endometrial Hand2 deletion in a mouse model and
found that the absence of Hand2 triggers pre-neoplastic alterations
with increasing age.
We provide supporting evidence to suggest that PCGT
methylation, as exemplified here by HAND2 DNAme (the hub of
the top-ranked EpiMod hotspot), is not merely a passive epigenetic
feature of cancer but plays a functional role that facilitates the
carcinogenic process—i.e., in the development of endometrial
premalignancy (CAH).
HAND2 exhibits all the features of a classical tumour suppressor
gene: (1) it is activated by progesterone, which is considered to be
the ultimate endometrial tumour suppressor [14]; (2) it suppresses
oestrogen-mediated signals (e.g., FGFs) that stimulate the endo-
metrial epithelium [23] and are known to be involved in
endometrial carcinogenesis [37]; (3) it is robustly suppressed in
endometrial cancer by means of a covalent modification (meth-
ylation) of DNA; (4) it is the hub of a differential methylation
hotspot that ranked top among all hotspots in an integrative
epigenome-interactome network analysis; (5) DNAme of HAND2
increases with the development of endometrial premaligancy and
is associated with resistance to progesterone; and (6) deletion of
Hand2 in mice leads to morphological as well as molecular changes
that precede invasive endometrial cancer.
When compared to other frequent DNA-based alterations in
endometrial cancers such as p53, PTEN, and PIK3CA mutations or
microsatellite instability [38,39], HAND2 DNAme was found to be
the most common DNA-based alteration. Applying a conservative
threshold (the highest methylation level in normal endometrial
samples), HAND2 hypermethylation is present in .90% of all
endometrioid endometrial cancers. Detection of HAND2 DNAme
could potentially afford multiple clinical utilities including risk
prediction and early detection of endometrial cancer in women
presenting with postmenopausal bleeding, as well as prediction of
treatment response for confirmed disease.
Whilst it is currently technologically impossible to specifically
hypermethylate and silence individual genes, we also show that
mice exhibiting a knock-out of Hand2 in progesterone-expressing
endometrial cells develop abnormal endometrial histology with
increasing age. Importantly, the observed lesions mimic CAH,
which represents the initial stage of endometrial cancer develop-
ment in humans and is associated with suppression of genes,
including PTEN, that are known to be frequently mutated and
suppressed in human endometrial cancers.
Our data have two major implications. First, we provide
supporting evidence that suggests epigenetic aberrations, i.e., stem
cell PCGT DNAme, are functionally important and contribute
significantly to carcinogenesis and are not simply passive cancer
characteristics. Although we and others have previously demon-
strated that PCGT methylation is a hallmark of cancer [5,21,40–
43], it has remained unclear whether methylation of these genes
represents an epiphenomenon or has functional relevance in early
carcinogenesis. We believe our research approach—i.e., (1)
application of the FEM algorithm followed by (2) analysis of
identified functional EpiMod hotspots in early stage prema-
lignancy and malignancy in humans, and finally, (3) comparative
assessment of results using conditional knock-out animal models—
presents an analytical strategy that could be applied by others to
discover those genes that are both epigenetically regulated and
functionally important in the development of other cancers.
Second, endometrial cancer is the most common of all
gynaecological cancers, and its incidence is continuing to rise
dramatically owing to the current ageing and obesity epidemics.
Consequently, novel strategies to prevent and/or early detect this
disease are very much required. The potential clinical utility of
HAND2 DNAme analysis is significant in that it could be applied
to triage women who present with postmenopausal bleeding
(currently ,90% of women who present with this symptom and
are cancer-free must undergo endometrial biopsy for a definitive
diagnosis) and could be further employed as a test to early detect
endometrial cancer and predict response to preventative treat-
ment.
Despite the notable findings and comprehensive nature of this
study, we acknowledge that some study limitations remain: (1) the
immediate consequences of HAND2 silencing in endometrial
stroma cells on both the molecular and cellular level require
further assessment using laser-assisted micro-dissection and various
primary cell culture assays; (2) suggested clinical applications of a
HAND2 methylation test, i.e., for the purposes of early detection
and treatment prediction would require validation in both
prospective settings and clinical trials; and (3) further studies need
to be performed to address the role of epigenetic alterations in the
less common non-endometrioid endometrial cancer subtypes
including serous and clear cell endometrial cancers.
Supporting Information
Figure S1 DNA methylation level at specific CpGs of
seven genes known to be hypermethylated [20]. DNAme
was analysed by means of the Illumina Infinium HumanMethy-
lation27K array in 23 normal and 64 endometrial cancer samples
(n=12) at 8–10 (A and D), 24–32 (B and E), and 40–48 (C and F) wk of age are shown. Note the increase in the gland/stroma ratio and the irregularity
in the shape and size of the glands in Hand2d/d uteri compared to Hand2f/f uteri. G, gland; S, stroma. Magnification 206. (G) Boxplots comparing the
number of glands in uterine sections of Hand2f/f (control) and Hand2d/d (null) mice as a function of age. The number of endometrial glands was
determined by counting the glands from three different regions of the uterine horn and is expressed as mean 6 standard error. Statistical analysis
was performed using a t-test. Boxes are median (interquartile range), and whiskers indicate range.
doi:10.1371/journal.pmed.1001551.g004
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(Set 1; Table S1). b-values for all CpGs for the seven genes
indicated are blotted, and a Wilcoxon rank sum test p-value is
provided. C, cancer; N, normal.
(TIF)
Figure S2 Phospho-FSR2 and PTEN immunofluores-
cence negative controls. Magnification 406 and 206,
respectively.
(TIF)
Figure S3 The Functional Epigenetic Modules algo-
rithm: integration of epigenome-transcriptome-interac-
tome data to identify epigenetic drivers in cancer. Step 1:
Differential methylation statistics are overlaid onto a protein
interaction network, and hotspots of differential methylation are
inferred using a module detection algorithm as described in
Methods (blue = hypermethylation in cancer, orange =hypo-
methylation in cancer). Step 2: Differential expression statistics
are overlaid onto the same protein interaction network, and
hotspots of simultaneous differential methylation and differential
expression are inferred using the module detection algorithm on
the integrated weighted network as described in Methods
(red = overexpression in cancer, green =underexpression in can-
cer).
(TIF)
Figure S4 Principal component analysis in Set 1. Left
panel is a scatterplot of the weights in the top two principal
component analysis components. Right panel is a boxplot of the
weights in the top singular principal component analysis
component. Wilcoxon rank sum test p-value for a difference
between the weights in normal and cancer tissue is given.
(TIF)
Figure S5 HAND2 mRNA expression in normal and
cancerous endometrium (Set 2). Wilcoxon rank sum test p-
value is given. EC, endometrial cancer; N, normal.
(TIF)
Figure S6 Heatmap of Illumina Infinium HumanMethy-
lation27K DNA methylation levels (Set 1) of significantly
hypermethylated HAND2 epigenetic module members.
(TIF)
Figure S7 Scatterplots of HAND2 versus DCC DNA
methylation and mRNA expression. Left panel: Scatterplot
of HAND2 and DCC DNAme levels (Set 1). Right panel:
Scatterplot of HAND2 and DCC mRNA expression levels (Set 2).
Green and red indicate normal and cancer, respectively.
(TIF)
Figure S8 Correlation between two differentially locat-
ed CpG sites analysed using the Illumina Infinium
HumanMethylation27K bead array, and two differen-
tially located MethyLight reactions (designed to cover
the Illumina CpG sites) for the HAND2 gene. Left panel:
cg02774439 represents a CpG site located +127 bp downstream of
the transcription start site within the CpG island in the 59
untranslated region, and cg01580681 is located +1,362 bp
downstream of the transcription start site within exon 1. Right
panel: The MethyLight reaction ML_HAND2_I (incorporating
cg02774439)—a 83-bp real-time PCR reaction beginning +51
downstream of the transcription start site within the CpG island in
the 59 untranslated region—was compared with ML_HAND2_II
(incorporating cg01580681)—a 78-bp real-time PCR reaction
beginning +1,355 downstream of the transcription start site within
exon 1. Refer to Figure 1E for a schematic of the CpG locations
within the HAND2 gene.
(TIF)
Figure S9 Association between sequence variations in
the 59 region ofHAND2 and DNAmethylation. cg02774439
represents a CpG site located +127 bp downstream of the
transcription start site within the CpG island in the 59 untranslated
region, and cg01580681 is located +1,362 bp downstream of the
transcription start site within exon 1. In 23 endometrial cancer
samples, the entire region +1 transcription start site to +2,071 bp
downstream of the transcription start site was sequenced (Table
S5), and HAND2 DNAme levels were plotted for samples with
sequence variants absent or present in the 2,070-bp region.
(TIF)
Figure S10 Sensitivity and specificity of vaginal swab
HAND2methylation to diagnose stage greater than stage
1A endometrial cancer. ROC curves measuring the sensitivity
and specificity of HAND2 methylation in vaginal swabs to
discriminate women with a greater than stage 1A endometrial
cancer (n=13) from women with non-cancerous causes (n=17) for
postmenopausal bleeding. AUC and p-values (P) as specified (see
also Table S3).
(TIF)
Figure S11 Increased mitotic activity in Hand2d/d
knock-out mice versus controls. Uterine sections from
Hand2f/f (A) and Hand2d/d (B) mice (n=5) were subjected to
immunohistochemical staining with Ki67, a marker of cell
proliferation. Note the hyperproliferative glandular epithelium in
uteri lacking Hand2. L, G, and S indicate lumen, glands, and
stroma, respectively. The measurement of glandular epithelial cell
proliferation in uterine sections of Hand2f/f and Hand2d/d mice was
performed by immunostaining for Ki67. Digital images of
immunostained sections of uteri from Hand2f/f and Hand2d/d mice
(n=5) were captured and analysed. Quantification of Ki67-
positive cells was performed using Image J software (http://rsb.
info.nih.gov/ij/) with cell counter plug-in. For each sample, the
Ki67-positive cells and total number of cells per field were counted
for an average of 8–10 fields per section, and the average
percentage positive cells was calculated. Data are expressed as
mean 6 standard error of the mean, and comparisons between
experimental groups are made (C) using analysis of variance.
Statistical significance was assigned at p,0.05.
(TIF)
Figure S12 P53 immunofluorescence in Hand2d/d
knock-out mice versus controls. (A–D) Uterine sections
from Hand2f/f (A and C) (n=3) and Hand2d/d mice (B and D) (n=3)
Figure 5. Endometrial pre-invasive neoplastic changes in Hand2 conditional knock-out mice. (A and B) Hematoxylin and eosin staining of
uterine sections from Hand2f/f (A) and Hand2d/d (B) mice (n= 5). Representative uterine sections obtained from mice at 24–48 wk of age are shown.
Closely packed, irregular-shaped glands and features consistent with CAH are evident in uteri lacking Hand2. Note multiple layers of glandular
epithelium in Hand2d/d uteri. Magnification 406. (C–F) Phospho-FRS2 immunofluorescence in sections from Hand2f/f (C) (boxed region in [C] further
magnified in [D]) and Hand2d/d (E) (boxed region in [E] further magnified in [F]) mice (n=3). Magnification 206 (C and E) and 406 (D and F). (G–J)
PTEN immunofluorescence in sections from Hand2f/f (G) (boxed region in [G] further magnified in [H]) and Hand2d/d (I) (boxed region in [I] further
magnified in [J]) mice. Magnification 206 (G and I) and 406 (H and J) (n= 3).
doi:10.1371/journal.pmed.1001551.g005
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were subjected to immunofluorescence staining with p53 antibody.
Magnification 206 (A and B) and 406 (C and D). (E) negative
control. Note there is no difference in p53 staining between
Hand2f/f and Hand2d/d mice.
(TIF)
Table S1 Associations of HAND2 DNAme and clinico-
pathological data for sample Set 1.
(XLS)
Table S2 HAND2 methylation (MethyLight reaction
ML_HAND2_II in Figure 1E) in Set 3.
(XLS)
Table S3 HAND2 methylation in vaginal swabs from
women with postmenopausal bleeding (Set 4).
(XLS)
Table S4 Clinical information for patients undergoing
treatment with progesterone (Set 6).
(XLS)
Table S5 HAND2 sequencing results (Sanger sequenc-
ing) in Set 1.
(XLS)
Table S6 Ranked list of genes hypermethylated in
cancerous compared to normal endometrium.
(XLS)
Table S7 Gene Set Enrichment Analysis of the top
hypermethylated genes in endometrial cancer.
(XLS)
Table S8 Gene Set Enrichment Analysis of the top
hypomethylated genes in endometrial cancer.
(XLS)
Table S9 Ranked list of top 19 epigenetic modules from
the epigenome-interactome analysis.
(XLS)
Table S10 Detailed compositions of the top 19 epige-
netic modules.
(XLS)
Table S11 Gene Set Enrichment Analysis of those genes
comprising each of the 19 top-ranked epigenetic mod-
ules.
(XLS)
Table S12 HAND2 methylation (Illumina Infinium Hu-
manMethylation27K array data) in Set 1 and detailed
associated molecular characteristics of the individual
tumours.
(XLS)
Text S1 Supplementary methods.
(DOCX)
Text S2 ARRIVE document.
(DOC)
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Editors’ Summary
Background. Cancer, which is responsible for 13% of global
deaths, can develop anywhere in the body, but all cancers
are characterized by uncontrolled cell growth and reduced
cellular differentiation (the process by which unspecialized
cells such as ‘‘stem’’ cells become specialized during
development, tissue repair, and normal cell turnover).
Genetic alterations—changes in the sequence of nucleotides
(DNA’s building blocks) in specific genes—are required for
this cellular transformation and subsequent cancer develop-
ment (carcinogenesis). However, recent evidence suggests
that epigenetic modifications—reversible, heritable changes
in gene function that occur in the absence of nucleotide
sequence changes—may also be involved in carcinogenesis.
For example, the addition of methyl groups to a set of genes
called stem cell polycomb group target genes (PCGTs;
polycomb genes control the expression of their target genes
by modifying their DNA or associated proteins) is one of the
earliest molecular changes in human cancer development,
and increasing evidence suggests that hypermethylation of
PCGTs is an epigenetic hallmark of cancer.
Why Was This Study Done? The methylation of PCGTs,
which is triggered by age and by environmental factors that
are associated with cancer development, reduces cellular
differentiation and leads to the accumulation of undifferen-
tiated cells that are susceptible to cancer development. It is
unclear, however, whether epigenetic modifications have a
causal role in carcinogenesis. Here, the researchers investi-
gate the involvement of epigenetic factors in the develop-
ment of endometrial (womb) cancer. The risk of endometrial
cancer (which affects nearly 50,000 women annually in the
United States) is largely determined by environmental and
lifestyle factors. Specifically, the risk of this cancer is
increased in women in whom estrogen (a hormone that
drives cell proliferation in the endometrium) is functionally
dominant over progesterone (a hormone that inhibits
endometrial proliferation and causes cell differentiation);
obese women and women who have taken estrogen-only
hormone replacement therapies fall into this category. Thus,
endometrial cancer is an ideal model in which to study
whether epigenetic mechanisms underlie carcinogenesis.
What Did the Researchers Do and Find? The researchers
collected data on genome-wide DNA methylation at cyto-
sine- and guanine-rich sites in endometrial cancers and
normal endometrium and integrated this information with
the human interactome and transcriptome (all the physical
interactions between proteins and all the genes expressed,
respectively, in a cell) using an algorithm called Functional
Epigenetic Modules (FEM). This analysis identified HAND2 as
the hub of the most highly ranked differential methylation
hotspot in endometrial cancer. HAND2 is a progesterone-
regulated stem cell PCGT. It encodes a transcription factor
that is expressed in the endometrial stroma (the connective
tissue that lies below the epithelial cells in which most
endometrial cancers develop) and that suppresses the
production of the growth factors that mediate the growth-
inducing effects of estrogen on the endometrial epithelium.
The researchers hypothesized, therefore, that epigenetic
deregulation of HAND2 could be a key step in endometrial
cancer development. In support of this hypothesis, the
researchers report that HAND2 methylation was increased in
premalignant endometrial lesions (cancer-prone, abnormal-
looking tissue) compared to normal endometrium, and was
associated with suppression of HAND2 expression. Moreover,
a high level of endometrial HAND2 methylation in premalig-
nant lesions predicted a poor response to progesterone
treatment (which stops the growth of some endometrial
cancers), and analysis of HAND2 methylation in endometrial
secretions collected from women with postmenopausal
bleeding (a symptom of endometrial cancer) accurately
identified individuals with early stage endometrial cancer.
Finally, mice in which the Hand2 gene was specifically
deleted in the endometrium developed precancerous
endometrial lesions with age.
What Do These Findings Mean? These and other
findings identify HAND2 methylation as a common, key
molecular alteration in endometrial cancer. These findings
need to be confirmed in more women, and studies are
needed to determine the immediate molecular and cellular
consequences of HAND2 silencing in endometrial stromal
cells. Nevertheless, these results suggest that HAND2
methylation could potentially be used as a biomarker for
the early detection of endometrial cancer and for predicting
treatment response. More generally, these findings support
the idea that methylation of HAND2 (and, by extension, the
methylation of other PCGTs) is not a passive epigenetic
feature of cancer but is functionally involved in cancer
development, and provide a framework for identifying other
genes that are epigenetically regulated and functionally
important in carcinogenesis.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001551
N The US National Cancer Institute provides information on
all aspects of cancer and has detailed information about
endometrial cancer for patients and professionals (in
English and Spanish)
N The not-for-profit organization American Cancer Society
provides information on cancer and how it develops and
specific information on endometrial cancer (in several
languages)
N The UK National Health Service Choices website includes
an introduction to cancer, a page on endometrial cancer,
and a personal story about endometrial cancer
N The not-for-profit organization Cancer Research UK pro-
vides general information about cancer and specific
information about endometrial cancer
N Wikipedia has a page on cancer epigenetics (note:
Wikipedia is a free online encyclopedia that anyone can
edit; available in several languages)
N The Eve Appeal charity that supported this research
provides useful information on gynecological cancers
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